Abstract
Abstract
Objective
Because the presence of immunocompetent cells in the myocardium is associated with the pathological stage and/or myocardial viability, we explored relationships between functional recovery after left ventricular assist device implantation and the distribution of immunocompetent cells in non-ischaemic dilated cardiomyopathy patients.
Methods
We reviewed 50 consecutive dilated cardiomyopathy patients implanted with HeartMate II at our institute between April 2013 and December 2018 who were treated with optimal medical therapy during left ventricular assist device support. Patients were stratified by improvement of the left ventricular ejection fraction at 6 months after implantation: ≥ 10% increase (Gr ≥ 10%), 5–10% (Gr 5–10%), and ≤ 5% (Gr ≤ 5%). T cells and macrophages were evaluated in the apical myocardium after left ventricular assist device implantation.
Results
During left ventricular assist device support, 12 patients underwent heart transplantation and 2 patients died. Four patients with Gr ≤ 5% were readmitted because of congestive heart failure, but none with Gr ≥ 10%. Macrophages and T cells in the left ventricular myocardium with Gr ≥ 10% were significantly more present compared to those in other groups.
Conclusions
The distribution of immunocompetent cells in the left ventricular myocardium might predict myocardial viability of this pathology after implantation.
Publisher
Springer Science and Business Media LLC
Subject
Cardiology and Cardiovascular Medicine,Pulmonary and Respiratory Medicine,General Medicine,Surgery
Reference17 articles.
1. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Böhm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J. 2016;37:1850–8.
2. Drakos SG, Kfoury AG, Stehlik J, Selzman CH, Reid BB, Terrovitis JV, et al. Bridge to recovery: understanding the disconnect between clinical and biological outcomes. Circulation. 2012;126:230–41.
3. Maybaum S, Mancini D, Xydas S, Starling RC, Aaronson K, Pagani FD, et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the LVAD working group. Circulation. 2007;115:2497–505.
4. Dandel M, Weng Y, Siniawski H, Potapov E, Drews T, Lehmkuhl HB, et al. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. Circulation. 2008;118:S94–105.
5. Lamarche Y, Kearns M, Josan K, Bashir J, Ignaszewski A, Kaan A, et al. Successful weaning and explantation of the heartmate II left ventricular assist device. Can J Cardiol. 2011;27:358–62.